Anti-CD79b (clone hu2F2.D7)-BMPEO-DM1 ADC

  • 1.00 Dollar US$
  • Published date: November 10, 2017
  • Modified date: November 10, 2017
    • Shirley, New York, United States

This ADC product is comprised of an anti-CD79B monoclonal antibody (clone hu2F2.D7) conjugated via a BMPEO linker to DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, DM1 binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation.
"Derived from Maytansinoid,a group of cytotoxins structurally similar to rifamycin, geldanamycin, and ansatrienin. The eponymous natural cytotoxic agent maytansine is a 19-member lactam (ansa
macrolide) structure originally isolated from the Ethiopian shrub Maytenus ovatus. Maytansinoids can bind to tubulin at or near the vinblastine-binding site, which interfere the formation of microtubules and depolymerize already formed microtubules, inducing mitotic arrest in the intoxicated cells."

Result 0 votes
1 votes

Useful information

  • Avoid scams by acting locally or paying with PayPal
  • Never pay with Western Union, Moneygram or other anonymous payment services
  • Don't buy or sell outside of your country. Don't accept cashier cheques from outside your country
  • This site is never involved in any transaction, and does not handle payments, shipping, guarantee transactions, provide escrow services, or offer "buyer protection" or "seller certification"

Related listings

  • NHP Disease Models

    NHP Disease Models

    Drug Development (New York ) May 22, 2018 Check with publisher

    Creative Animodel develops a series of animal disease models for distinct in-vivo tests including drug toxicology and safety, PD/PK, disease pathogenic mechanism and therapeutic studies. NHP models can be customized based on requirements or establish...

  • NonHuman Primate Capability

    NonHuman Primate Capability

    Drug Development (New York ) May 22, 2018 Check with publisher

    Creative Animodel draws on wide-ranging expertise in genetic toxicology to conduct regulatory testing efficiently. We can deliver the data that you need for helping understand the potential adverse effects and the mode-of-action related to humans. ht...

  • Gastrointestinal Toxicology

    Gastrointestinal Toxicology

    Drug Development (New York ) May 22, 2018 Check with publisher

    With years of experience, Creative Animodel offers a wide range of toxicology and safety pharmacology assays. Our gastrointestinal toxicology services provide clients with high-quality toxicity data to support drug discovery and development in a cost...